Foghorn Therapeutics and Loxo Oncology at Lilly, a research and development group of Eli Lilly, have entered into a strategic collaboration to create novel oncology medicines by applying Foghorn’s proprietary Gene Traffic Control platform, a tool for understanding and modulating the chromatin regulatory system which regulates gene expression by directing the movement of molecules that […]

Blueprint Medicines will acquire San Diego-based Lengo Therapeutics, a privately held precision oncology company, for $250 million in cash plus up to $215 million in additional potential payments based on the achievement of certain regulatory approval and sales-based milestones. Lengo Therapeutics is developing novel, small molecule precision therapeutics that target driver mutations in oncology. The company’s initial focus is […]

Vertex Pharmaceuticals has announced positive results from a small, Phase 2 proof-of-concept (POC) study of investigational drug VX-147 in patients with APOL1-mediated kidney disease. Based on these data, Vertex plans to advance VX-147 into pivotal development in Q1 2022 as a potential first-in-class therapy for the more than 100,000 patients with kidney disease mediated by […]

Dicerna Pharmaceuticals, a biopharmaceutical company focused on the development of investigational ribonucleic acid interference (RNAi) therapeutics, is being acquired by Danish drug giant Novo Nordisk for $38.25 per share in cash, which represents a total equity value of $3.3 billion and a premium of 80% to Dicerna’s closing price on November 17, 2021. Dicerna’s RNAi technology platform enables access to […]